Patented At-Home Vision Testing Platform

Business Overview:

A rare opportunity to acquire the only fully built, clinically validated, FDA-registered at-home vision diagnostics platform shipping at scale. A 29-patent portfolio pairs with proprietary, MIT-licensed optical technology and a HIPAA-compliant telehealth network that delivers prescriptions across 40 U.S. states. Over 50,000 devices sold in 150+ countries over eight years of commercial operation - with zero product defects, zero MDRs, and zero product litigation throughout the entire history of the business.

This is a continuation of the commercialization play, not a speculative technology-development bet.

More than $31 million has been invested to date for software and product development, inventory, and marketplace testing.

WHY THIS IS EXCEPTIONAL
◉ Patented, smartphone-based vision diagnostics platform - test vision, measure refractive error, and obtain prescriptions remotely.
◉ Exclusive license to MIT inverse Shack-Hartmann refraction technology — the foundational science behind the platform.
◉ 29-patent portfolio (granted plus pending) covering smartphone diagnostics, optical measurement, automated vision tracking, and PD measurement.
◉ Seven FDA-registered medical devices and apps - refraction, visual acuity, contrast, color, Amsler, PD, and reading-numbers measurement.
◉ Full compliance stack: ISO 13485, ISO 9001, HIPAA, and a state medical device manufacturer license - a five-cert posture few digital-health platforms hold at once.
◉ Four registered clinical trials on ClinicalTrials.gov, including a non-inferiority study versus phoropter and autorefractor, plus multiple CES Innovation Awards and a 2020 Frost Radar award.
◉ Blue-chip B2B relationships — including a national pharmacy chain, a major health system, and a leading online eyewear retailer (founded by the company's own co-founder).
◉ Proprietary longitudinal vision dataset across the deployed fleet - a substrate for AI-driven diagnostics, predictive care, and population-health analytics.
◉ Substantial finished-goods inventory plus contract-manufacturing relationships in place - supporting immediate scale with no manufacturing lead-time exposure.
◉ Clean financial posture: no debt, no loans, capital on hand, and a prior $25M strategic asset transaction demonstrating realized value in the IP.

THE UPSIDE FOR STRATEGIC AQUIRER
The platform is fully developed but deliberately under-commercialized - the remaining work is commercial scale, not technology build-out. Multiple paths to value creation:
◉ Scale direct-to-consumer adoption and conversion from testing to prescription to eyewear purchase.
◉ Build recurring revenue — vision-tracking subscriptions and Rx renewal services across the installed base.
◉ Expand B2B partnerships with optical retailers, clinics, telehealth platforms, and pharmacies.
◉ Monetize the proprietary dataset for AI diagnostics and predictive care.
◉ Expand into global and underserved markets where low-cost remote diagnostics travel well.

NDA is required to secure the comprehensive Confidential Information Memorandum (CIM) crafted by ProNova Partners.

Contact the Seller:

To request more information regarding this listing, simply check the ADD TO REQUEST INFO BASKET button (above Quick Facts) and when you are done searching and have made all your selections, simply click on the REQUEST FREE INFO button at the bottom of this page.

Property Features and Assets:

In CIM, NDA required.

Market Competition and Expansion:

In CIM, NDA required.

Reason for Selling:

Position the Company for growth and continued global commercialization. Kindly ask the seller for more information.

Additional Details:

Relevant Links:

• View more California businesses for sale
• View more Businesses For Sale in the same industry
• Sell a business online
• Find a business broker